A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors Abstract #1505

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Aim(s): Assess the effectiveness of the NETest as a PRRT predictive marker.
Materials and methods: 177Lu-octreotate treated NETs (n=54) followed for 33 months. Histological grade, somatostatin receptor imaging (SRI), CgA (ELISA, normal<108ng/ml) and NETest (qPCR with multianalyte algorithmic analyses) were evaluated. A mathematical response index comprising NETest genes regulating metabolism and growth factor signaling and grade was developed as a Predictive Quotient Index (PQI). Response was assessed by RECIST.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Keywords: NETest, PRRT

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result